Literature DB >> 30678416

[Clinical significance of exosomal miR-1231 in pancreatic cancer].

S L Chen1, M Ma1, L Yan1, S H Xiong2, Z Liu1, S Li1, T Liu1, S Shang1, Y Y Zhang1, H Zeng1, H L Xie3, C H Zuo1.   

Abstract

Objective: To investigate the expression and clinical significance of exosomal miR-1231 in plasma of pancreatic cancer (PC) patients and pancreatic cancer cells.
Methods: A total of 16 patients who were diagnosed with pancreatic cancer in Hunan Cancer Hospital were collected from April 2016 to August 2017. Meanwhile, 16 healthy volunteers were recruited as the healthy control group at the same period. The plasma exosomes were extracted, and the levels of miR-1231 were detected by qRT-PCR in PC and healthy control groups. Moreover, the clinicopathological significance of exosomal miR-1231 expression was analyzed. Furthermore, the expression of exosomal miR-1231 was detected in several pancreatic cancer cells (MIA PaCa-2, PANC-1, SW1990, AsPC-1 and BxPc-3) and two normal pancreatic epithelial cells (HPDE and human primary pancreatic epithelial cell).
Results: qRT-PCR results showed that the expression level of miR-1231 in plasma exosomes of pancreatic cancer patients (1.06±0.46) was significantly lower than that in healthy controls (2.30±0.99; P<0.05). The levels of exosomal miR-1231 in patients with stage Ⅰ-Ⅱ (1.515±0.531), no distant metastasis (1.236±0.461) and no lymph node metastasis (1.337±0.522) were significantly higher than those with stage Ⅲ-Ⅳ (0.848±0.224), distant metastasis (0.757±0.278) and lymph node metastasis (0.838±0.261), respectively (P<0.05 for all). In addition, there were no correlation between exosomal miR-1231 expression and age, sex, smoking history, CA19-9 levels and tumor sites (P>0.05). Furthermore, the expression level of exosomal miR-1231 in pancreatic cancer cell lines (0.142±0.135) was significantly lower than that in normal epithelial cells (1.127±0.179; P<0.05). Conclusions: The downregulation of exosomal miR-1231 in plasma of pancreatic cancer patients and pancreatic cancer cells suggests that it is related to the initiation and development of PC. It may be a new diagnostic and prognostic marker for PC.

Entities:  

Keywords:  Clinicopathological features; Exosomes; MicroRNA-1231; Pancreatic neoplasms

Mesh:

Substances:

Year:  2019        PMID: 30678416     DOI: 10.3760/cma.j.issn.0253-3766.2019.01.008

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  6 in total

1.  Computational and Bioinformatics Methods for MicroRNA Gene Prediction.

Authors:  Ege Riza Karagur; Sakir Akgun; Hakan Akca
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.

Authors:  Behnoush Sohrabi; Behnaz Dayeri; Elahe Zahedi; Shahrouz Khoshbakht; Najme Nezamabadi Pour; Hamta Ranjbar; Abolfazl Davari Nejad; Mahdi Noureddini; Behrang Alani
Journal:  Cancer Gene Ther       Date:  2022-01-26       Impact factor: 5.854

3.  A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets.

Authors:  Yepeng Li; Shiqing Huang; Zhongheng Wei; Bo Yang
Journal:  Oncol Lett       Date:  2020-03-27       Impact factor: 2.967

4.  Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer.

Authors:  Song Shang; Jinfeng Wang; Shilin Chen; Renyun Tian; Hui Zeng; Liang Wang; Man Xia; Haizhen Zhu; Chaohui Zuo
Journal:  Cancer Med       Date:  2019-10-23       Impact factor: 4.452

Review 5.  Crosstalk between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in the Tumor Microenvironment Mediated by Exosomal MicroRNAs.

Authors:  Xiangyu Chu; Yinmo Yang; Xiaodong Tian
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208

Review 6.  Preclinical Experimental Applications of miRNA Loaded BMSC Extracellular Vesicles.

Authors:  Zafer Cetin; Eyup I Saygili; Gokhan Görgisen; Emel Sokullu
Journal:  Stem Cell Rev Rep       Date:  2021-01-04       Impact factor: 5.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.